# Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

> **NCT02128490** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 189 (actual)

## Conditions studied

- Gout
- Moderate Renal Impairment

## Interventions

- **DRUG:** Febuxostat IR
- **DRUG:** Febuxostat XR
- **DRUG:** Febuxostat placebo
- **DRUG:** Colchicine
- **DRUG:** Naproxen
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT02128490
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-09
- **Final completion:** 2015-10
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2016-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128490, "Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02128490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*